# Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer

Article · Heyrim Cho, Zuping Wang, Doron Levy

- Archive id: arxiv:2001.10573
- Published: 2020-01-28
- Venue: Journal of Theoretical Biology
- DOI: https://doi.org/10.1016/j.jtbi.2020.110403
- arXiv: https://arxiv.org/abs/2001.10573
- Citations: 11
- Source URL: https://arxiv.org/abs/2001.10573
- PDF: https://arxiv.org/pdf/2001.10573
- Provenance: arxiv

## Abstract

Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited success, so far, in treating solid cancers, it is increasingly successful, demonstrating to have a broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy), [Gene & Cell Therapy](https://space-kitty.com/topics/gene-cell-therapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.